

# Ten Year Financial Summary

<b>CONSOLIDATED BALANCE SHEET</b>										(₹ in million)
As at March 31,	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
<b>SOURCES OF FUNDS</b>										
<b>Shareholders' funds</b>										
Equity Share Capital	892.4	893.3	895.1	896.8	899.0	901.2	903.2	904.2	905.0	906.0
Reserves & Surplus	31,918.4	39,235.6	51,146.7	68,418.9	90,833.3	110,732.5	134,072.5	134,866.4	136,517.3	124,461.0
	32,810.8	40,128.9	52,041.8	69,315.7	91,732.3	111,633.7	134,975.7	135,770.6	137,422.3	125,367.0
<b>Non-Controlling Interest</b>	515.1	722.9	594.5	669.4	241.0	320.8	345.2	400.8	468.6	444.6
<b>Loans</b>	11,623.9	16,391.0	11,644.9	6,537.4	5,371.2	71,775.2	79,660.9	71,428.0	84,961.5	63,053.2
<b>Deferred Tax Liabilities (net)</b>	1,791.8	1,910.1	2,336.8	2,486.6	1,527.5	3,266.8	3,948.5	2,855.3	2,882.8	1,995.4
<b>Other Liabilities (incl. Provisions)</b>	14,502.0	20,669.3	22,520.6	23,051.2	33,737.7	39,252.1	47,142.5	52,599.1	53,758.5	58,978.3
<b>TOTAL</b>	<b>61,243.6</b>	<b>79,822.2</b>	<b>89,138.6</b>	<b>102,060.3</b>	<b>132,609.7</b>	<b>226,248.6</b>	<b>266,072.8</b>	<b>263,053.8</b>	<b>279,493.7</b>	<b>249,838.5</b>
<b>APPLICATION OF FUNDS</b>										
<b>Fixed Assets</b>										
Net Block	17,313.4	22,456.6	24,928.5	26,977.3	27,200.3	64,515.2	87,229.2	79,135.0	87,063.9	60,866.3
Capital Work-in-Progress (incl. Capital Advances)	5,319.3	4,973.7	3,909.0	4,110.2	6,745.3	32,145.5	24,639.0	26,555.6	17,293.9	10,953.4
	22,632.7	27,430.3	28,837.5	31,087.5	33,945.6	96,660.7	111,868.2	105,690.6	104,357.8	71,819.7
<b>Goodwill on Consolidation</b>	3,254.9	5,040.0	5,073.2	6,578.7	16,252.8	22,654.4	23,100.1	24,484.9	23,803.2	18,514.8
<b>Investments</b>	31.5	28.0	20.6	20.6	55.4	143.3	220.0	267.1	317.7	360.7
<b>Deferred Tax Assets (net)</b>	380.5	467.8	704.4	708.1	2,561.7	3,358.5	5,076.4	7,165.6	7,340.0	1,743.1
<b>Other Assets</b>										
Inventories	11,999.6	17,326.7	19,489.3	21,294.5	25,036.1	32,736.5	36,422.8	36,624.9	38,367.7	34,568.7
Receivables	12,556.4	17,800.1	21,869.9	24,641.0	26,475.2	45,487.6	43,073.4	51,922.1	51,498.0	54,459.3
Cash & Bank Balances (refer note iii)	4,201.4	4,024.7	4,348.8	9,739.1	21,304.7	8,237.7	28,135.4	16,431.7	32,523.5	47,935.2
Others	6,186.6	7,704.6	8,794.9	7,990.8	6,978.2	16,969.9	18,176.5	20,466.9	21,285.8	20,437.0
	34,944.0	46,856.1	54,502.9	63,665.4	79,794.2	103,431.7	125,808.1	125,445.6	143,675.0	157,400.2
<b>TOTAL</b>	<b>61,243.6</b>	<b>79,822.2</b>	<b>89,138.6</b>	<b>102,060.3</b>	<b>132,609.7</b>	<b>226,248.6</b>	<b>266,072.8</b>	<b>263,053.8</b>	<b>279,493.7</b>	<b>249,838.5</b>

CONSOLIDATED STATEMENT OF PROFIT AND LOSS										(₹ in million)
Year ended March 31,	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
<b>INCOME</b>										
Sales	57,421.7	70,017.2	95,235.3	111,671.2	126,932.2	137,578.7	171,198.0	155,598.4	143,180.5	151,428.0
Other Operating Income	1,121.5	1,232.1	1,796.7	1,999.3	1,703.0	4,976.7	3,745.3	2,443.1	3,465.1	2,319.6
Other Income	221.9	143.5	278.5	1,164.8	2,397.5	1,851.9	1,065.1	1,503.5	3,330.1	4,837.6
<b>Total Revenue</b>	<b>58,765.1</b>	<b>71,392.8</b>	<b>97,310.5</b>	<b>114,835.3</b>	<b>131,032.7</b>	<b>144,407.3</b>	<b>176,008.4</b>	<b>159,545.0</b>	<b>149,975.7</b>	<b>158,585.2</b>
<b>EXPENSES</b>										
Cost of Materials	22,379.3	26,039.0	35,485.0	38,173.8	41,570.4	43,325.7	50,014.3	52,744.0	49,460.9	54,306.0
Employee Benefits Expense	7,675.6	9,695.3	12,666.2	14,646.5	17,473.4	21,416.2	28,495.2	28,647.1	27,701.7	29,868.4
Manufacturing and Other Expenses	16,709.9	21,067.9	26,181.9	30,822.3	33,395.5	40,960.0	51,502.4	45,175.3	43,875.8	46,025.2
<b>Total Expenses</b>	<b>46,764.8</b>	<b>56,802.2</b>	<b>74,333.1</b>	<b>83,642.6</b>	<b>92,439.3</b>	<b>105,701.9</b>	<b>130,011.9</b>	<b>126,566.4</b>	<b>121,038.4</b>	<b>130,199.6</b>
<b>Profit before Interest, Depreciation &amp; Tax</b>	<b>12,000.3</b>	<b>14,590.6</b>	<b>22,977.4</b>	<b>31,192.7</b>	<b>38,593.4</b>	<b>38,705.4</b>	<b>45,996.5</b>	<b>32,978.6</b>	<b>28,937.3</b>	<b>28,385.6</b>
Finance Cost	344.8	354.7	409.5	266.5	98.1	594.7	1,525.3	2,043.5	3,024.9	3,629.8
Depreciation and Amortisation	1,711.8	2,275.2	3,321.9	2,609.7	4,347.0	4,871.3	9,122.3	10,858.7	8,460.5	9,702.2
Profit before Exceptional Items & Tax	9,943.7	11,960.7	19,246.0	28,316.5	34,148.3	33,239.4	35,348.9	20,076.4	17,451.9	15,053.6
Exceptional Items (Refer note iv)	-	-	-	-	-	-	-	14,643.5	3,399.8	7,520.7
<b>Profit before Tax</b>	<b>9,943.7</b>	<b>11,960.7</b>	<b>19,246.0</b>	<b>28,316.5</b>	<b>34,148.3</b>	<b>33,239.4</b>	<b>35,348.9</b>	<b>5,432.9</b>	<b>14,052.1</b>	<b>7,532.9</b>
Current Tax	1,176.3	2,756.2	5,829.0	9,536.0	10,041.6	11,433.5	10,882.1	5,349.8	8,496.8	6,869.7
Deferred Tax	(26.5)	329.4	12.6	85.5	(337.6)	(840.1)	(1,097.0)	(2,465.2)	382.6	4,701.4
<b>Net Profit/(Loss) before Discontinued Operations, Share of Profit from Jointly Controlled Entity, Non-Controlling Interest and Share of Loss in Associates</b>	<b>8,793.9</b>	<b>8,875.1</b>	<b>13,404.4</b>	<b>18,695.0</b>	<b>24,444.3</b>	<b>22,646.0</b>	<b>25,563.8</b>	<b>2,548.3</b>	<b>5,172.7</b>	<b>(4,038.2)</b>
Profit from Discontinued Operations	-	-	-	-	-	-	-	-	944.6	1,301.0
Share of Profit from Jointly Controlled Entity	-	-	-	-	-	49.0	82.5	35.2	37.5	39.4
Share of Profit/(Loss) attributable to Non-Controlling Interest	148.4	198.6	262.8	331.3	411.9	87.6	71.7	70.9	89.3	(3.9)
Share of Loss in Associates	20.0	-	-	-	-	-	-	-	-	-
<b>Net Profit/(Loss)</b>	<b>8,625.5</b>	<b>8,676.5</b>	<b>13,141.6</b>	<b>18,363.7</b>	<b>24,032.4</b>	<b>22,607.4</b>	<b>25,574.6</b>	<b>2,512.6</b>	<b>6,065.5</b>	<b>(2,693.9)</b>

**Notes :**

- i) Figures are suitably regrouped to make them comparable.
- ii) The company has transitioned the basis of accounting from Indian generally accepted accounting principles ("GAAP") to Ind AS with effect from April 1, 2016. Accordingly, Balance Sheet for 2015 onwards and Statement of Profit and Loss for 2016 onwards are as per Ind AS.
- iii) Cash and bank balances includes Current Investments and Non Convertible Debentures having maturity more than 12 months which represents investments of surplus funds.
- iv) Exceptional item for 2020 pertains to Profit/Loss on divestment of subsidiaries in Japan (Kyowa Pharmaceutical & Kyowa CritiCare), Impairment of intangible assets and Settlement with the State of Texas. Exceptional item for 2019 pertains to Provision for fine to European Commission and for 2018 pertains to Impairment of intangible assets.